Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1

Conditions

Multiple Myeloma 152Lymphoma, Mantle-Cell 30Lymphoma, Non-Hodgkin 22Lymphoma, Follicular 22Lymphoma 22Recurrence 21Neoplasms, Plasma Cell 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Leukemia, Myeloid, Acute 12Waldenstrom Macroglobulinemia 11Lymphoma, Large B-Cell, Diffuse 11Immunoglobulin Light-chain Amyloidosis 10Neoplasms 8Lymphoma, B-Cell, Marginal Zone 8Leukemia, Lymphocytic, Chronic, B-Cell 8Lymphoma, B-Cell 7Leukemia 6Carcinoma, Non-Small-Cell Lung 6Myelodysplastic Syndromes 5Hematologic Neoplasms 5Brain Neoplasms 5Amyloidosis 5Lymphoma, Large-Cell, Immunoblastic 4Hematologic Diseases 4Congenital Abnormalities 4Prostatic Neoplasms 3Paraproteinemias 3Leukemia, Myelomonocytic, Acute 3Leukemia, Monocytic, Acute 3Leukemia, Erythroblastic, Acute 3

Interventions

X-Rays 6Magnetic Resonance Spectroscopy 6Specimen Handling 5Phantoms, Imaging 5Vincristine 4Nuclear Medicine Department, Hospital 4Doxorubicin 4Dactinomycin 4Radiotherapy 3Biopsy 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2erdafitinib 2Vemurafenib 2Radiotherapy, Conformal 2Radiation 2LY3023414 2Etoposide 2Cyclophosphamide 2Carboplatin 2thymoglobulin 1sargramostim 1pembrolizumab 1lorvotuzumab mertansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Wilms Tumor × Bortezomib × Clear all
NCT01827137 2024-09-19

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

Sellas Life Sciences Group

Phase 1/2 Completed
20 enrolled 9 charts
GenitourinaryPlasma cell

Multiple Myeloma, Wilms Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡